Related references
Note: Only part of the references are listed.Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain
Andrew D. Cook et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy
Helen L. Wright et al.
RHEUMATOLOGY (2012)
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Regulation of Systemic and Local Myeloid Cell Subpopulations by Bone Marrow Cell-Derived Granulocyte-Macrophage Colony-Stimulating Factor in Experimental Inflammatory Arthritis
Andrew D. Cook et al.
ARTHRITIS AND RHEUMATISM (2011)
The encephalitogenicity of TH17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF
Mohamed El-Behi et al.
NATURE IMMUNOLOGY (2011)
Greater Likelihood of Remission in Rheumatoid Arthritis Patients Treated Earlier in the Disease Course: Results From the Consortium of Rheumatology Researchers of North America Registry
Daniel E. Furst et al.
ARTHRITIS CARE & RESEARCH (2011)
Direct Comparison of Treatment Responses, Remission Rates, and Drug Adherence in Patients With Rheumatoid Arthritis Treated With Adalimumab, Etanercept, or Infliximab Results From Eight Years of Surveillance of Clinical Practice in the Nationwide Danish DANBIO Registry
Merete Lund Hetland et al.
ARTHRITIS AND RHEUMATISM (2010)
The Dynamics of Macrophage Lineage Populations in Inflammatory and Autoimmune Diseases
John A. Hamilton et al.
ARTHRITIS AND RHEUMATISM (2009)
G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis
Ann L. Cornish et al.
NATURE REVIEWS RHEUMATOLOGY (2009)
GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival
Ivo Sonderegger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification
Stefan Steidl et al.
MOLECULAR IMMUNOLOGY (2008)
Colony-stimulating factors in inflammation and autoimmunity
John A. Hamilton
NATURE REVIEWS IMMUNOLOGY (2008)
GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice
C. Plater-Zyberk et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: the metacarpophalangeal joints
P Conaghan et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
LBA van de Putte et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis
TL Bonfield et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2002)
Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease
AD Cook et al.
ARTHRITIS RESEARCH (2001)
Share Paper
